This study is currently not recruiting participants.

A Phase 1 Study of KBP-5209 in Patients With Advanced Solid Tumors

Study of Investigational Medication for Advanced Solid Tumors

Not Recruiting
18 years - 100 years
All
Phase N/A
1 Location

Brief description of study.

The purpose of this study is to determine the maximum tolerated dose of KBP-5209 as a single agent when given orally to adult patients with advanced solid tumors that have progressed despite standard therapy, or where there is no standard therapy.

Detailed description of study

The purpose of this study is to determine the maximum tolerated dose of KBP-5209 as a single agent when given orally to adult patients with advanced solid tumors that have progressed despite standard therapy, or where there is no standard therapy.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Solid Tumor
  • Age: 18 years - 100 years
  • Gender: All

The purpose of this study is to determine the maximum tolerated dose of an investigational medication when given orally to adult patients with advanced solid tumors. These are cancers that have worsened despite usual treatments or for which no standard treatment exists.

Participants will receive the investigational medication alone. The study will monitor how much of the medication can be given safely and what side effects may occur.

  • Who can participate: Adults aged 18 and over with advanced solid tumors that have progressed despite standard therapy or for which no standard therapy is available.
  • Study details: Participants will take the investigational medication by mouth. The study will observe the effects and determine the safest dose.
Updated on 19 Feb 2024. Study ID: 1501374278 (5209-CPK-1001

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team